Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/121969
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMorató Arús, Xavier-
dc.contributor.authorLuján, Rafael-
dc.contributor.authorLópez-Cano, Marc-
dc.contributor.authorGandía Sánchez, Jorge-
dc.contributor.authorStagljar, Igor-
dc.contributor.authorWatanabe, Masahiko-
dc.contributor.authorCunha, Rodrigo A.-
dc.contributor.authorFernández Dueñas, Víctor-
dc.contributor.authorCiruela Alférez, Francisco-
dc.date.accessioned2018-04-30T12:35:31Z-
dc.date.available2018-04-30T12:35:31Z-
dc.date.issued2017-08-25-
dc.identifier.issn2045-2322-
dc.identifier.urihttp://hdl.handle.net/2445/121969-
dc.description.abstractG protein-coupled receptor 37 (GPR37) is an orphan receptor associated to Parkinson's disease (PD) neuropathology. Here, we identified GPR37 as an inhibitor of adenosine A2A receptor (A2AR) cell surface expression and function in vivo. In addition, we showed that GPR37 and A2AR do oligomerize in the striatum. Thus, a close proximity of GPR37 and A2AR at the postsynaptic level of striatal synapses was observed by double-labelling post-embedding immunogold detection. Indeed, the direct receptor-receptor interaction was further substantiated by proximity ligation in situ assay. Interestingly, GPR37 deletion promoted striatal A2AR cell surface expression that correlated well with an increased A2AR agonist-mediated cAMP accumulation, both in primary striatal neurons and nerve terminals. Furthermore, GPR37−/− mice showed enhanced A2AR agonist-induced catalepsy and an increased response to A2AR antagonist-mediated locomotor activity. Overall, these results revealed a key role for GPR37 controlling A2AR biology in the striatum, which may be relevant for PD management.-
dc.format.extent13 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherNature Publishing Group-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1038/s41598-017-10147-x-
dc.relation.ispartofScientific Reports, 2017, vol. 7, num. 1, p. 9452-
dc.relation.urihttps://doi.org/10.1038/s41598-017-10147-x-
dc.rightscc-by (c) Morató Arús, Xavier et al., 2017-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)-
dc.subject.classificationMalaltia de Parkinson-
dc.subject.classificationProteïnes G-
dc.subject.classificationAdenosina-
dc.subject.classificationMarcadors bioquímics-
dc.subject.classificationReceptors de neurotransmissors-
dc.subject.otherParkinson's disease-
dc.subject.otherG Proteins-
dc.subject.otherAdenosine-
dc.subject.otherBiochemical markers-
dc.subject.otherNeurotransmitter receptors-
dc.titleThe Parkinson's disease-associated GPR37 receptor interacts with striatal adenosine A2A receptor controlling its cell surface expression and function in vivo-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec679446-
dc.date.updated2018-04-30T12:35:31Z-
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/604102/EU//HBP-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid28842709-
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Publicacions de projectes de recerca finançats per la UE

Files in This Item:
File Description SizeFormat 
679446.pdf2.46 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons